Scientists have identified changes in immune cells associated with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), according to a study published this week, offering fresh hope for patients who often spend years seeking a diagnosis for the debilitating condition.
Researchers studying myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) have found measurable changes in immune cells among patients with the condition, a discovery that could help explain its origins and eventually lead to more reliable diagnostic tools.
The findings centre on blood samples taken from ME/CFS patients, including Ella Engel, who spent years visiting multiple specialists before receiving her diagnosis. Engel's case illustrates the diagnostic odyssey that is common among ME/CFS sufferers — a journey that frequently involves years of uncertainty, misdiagnosis, and dismissal.
ME/CFS is a complex, chronic illness characterised by profound fatigue that does not improve with rest, along with a range of symptoms including cognitive impairment, sleep disturbances, and post-exertional malaise — a worsening of symptoms following physical or mental activity. The condition affects an estimated tens of millions of people worldwide, yet its biological mechanisms have remained poorly understood, contributing to significant delays in diagnosis and a lack of approved treatments.
The immune cell changes identified in the new research may represent a biological signature of the condition, potentially moving ME/CFS research closer to an objective diagnostic test. Such a test would mark a significant shift from the current reliance on symptom-based criteria, which can be inconsistently applied across different clinical settings.
Interest in ME/CFS research has grown considerably since the COVID-19 pandemic, as many long COVID patients have presented with symptoms closely resembling ME/CFS. Some researchers now believe that studying the two conditions in parallel may accelerate understanding of both.
While the findings represent a meaningful step forward, scientists caution that further research is needed to confirm and build upon the results. Larger studies across diverse patient populations will be necessary to validate whether the immune cell changes are consistently present in ME/CFS patients and absent in those without the condition.
For patients like Engel, who have long advocated for greater scientific and medical attention to ME/CFS, studies of this nature are welcomed — not only for their scientific value, but for the broader recognition they bring to a condition that has often been met with scepticism.
Analysis
Why This Matters
- ME/CFS affects millions globally and has historically lacked objective biological markers, leaving patients without validated diagnostic tests or approved treatments — this research could change that.
- The overlap between ME/CFS and long COVID means any biological insights may have implications for a far larger patient population, potentially accelerating funding and research interest.
- A measurable immune cell signature could shift clinical practice, reducing the years-long diagnostic delays experienced by most patients.
Background
Myalgic encephalomyelitis/chronic fatigue syndrome has been documented in medical literature for decades, though it has periodically been dismissed or mischaracterised as a psychological condition rather than a physiological one. The name itself reflects two schools of thought — 'myalgic encephalomyelitis' emphasising neurological and physical involvement, and 'chronic fatigue syndrome' a term critics argue trivialises the illness's severity.
For much of the late 20th century, ME/CFS received comparatively little research funding relative to its disease burden. Advocacy groups, many led by patients and their families, pushed for greater scientific attention throughout the 1990s and 2000s. Progress was slow and sometimes controversial, including a disputed 2011 study that linked ME/CFS to a retrovirus — a finding that was ultimately retracted.
The COVID-19 pandemic became an unexpected catalyst for ME/CFS research. As millions of people developed persistent symptoms following acute COVID-19 infection — a phenomenon known as long COVID — researchers began noting the striking similarities to ME/CFS, prompting renewed investment and scientific interest in the underlying biology of post-infectious illness.
Key Perspectives
Patients and Advocacy Groups: Patients like Ella Engel, who endure lengthy diagnostic journeys, stand to benefit most from research that produces objective biological markers. Advocacy organisations have long argued that ME/CFS deserves the same rigorous scientific scrutiny as other chronic illnesses of comparable disease burden.
Researchers and Scientists: The scientific community views immune cell findings as a promising lead, though researchers consistently emphasise the need for replication in larger, more diverse cohorts before clinical applications can be developed. The immune system's complexity means causation and correlation must be carefully distinguished.
Clinicians and Health Systems: Some clinicians have historically been sceptical of ME/CFS diagnoses, partly due to the absence of objective tests. Biological evidence of immune involvement could shift clinical attitudes, though translating research findings into standard diagnostic practice typically takes years.
What to Watch
- Whether independent research groups are able to replicate the immune cell findings in larger patient cohorts across different countries and demographics.
- Funding announcements from major health research bodies — such as the US National Institutes of Health or the Australian National Health and Medical Research Council — that may signal growing institutional commitment to ME/CFS research.
- Progress in long COVID research and any formal links drawn between long COVID immune profiles and those now identified in ME/CFS patients.